NBIX · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$167.39-1.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 2, 2026
Just reported
From Neurocrine Biosciences, Inc.'s results release of November 2, 2026; its quarterly report has since been filed.
Actual
$1.12B
+41% y/y
+17% q/q
Guided
—
No guide given
Actual
$1.96
-3.9% y/y
+41% q/q
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.1B | $794.9M | +41.24% |
| Profit | $206.5M | $209.5M | -1.43% |
| Profit per share | $1.96 | $2.04 | -3.92% |
| Free Cash Flow | $383.6M | $214.3M | +79.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Neurocrine Biosciences, Inc. reported on November 2, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Our third quarter performance marks another important milestone in Neurocrine’s evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Neurocrine Biosciences, Inc.’s Item 2.02 8-K filed November 2, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Actual
$331.3M
+39% y/y
+119% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.